Genitourinary Oncology Program, Texas Oncology PA, Houston, TX 77598, USA.

The approval of sunitinib, sorafenib and temsirolimus has dramatically altered the management of renal cell carcinoma (RCC). Bevacizumab plus IFN may also be added to the therapeutic armamentarium. Axitinib (AG-013736) is an oral and selective tyrosine kinase inhibitor.

Data supporting the development of axitinib for RCC are reviewed.

Preclinical and clinical data available for axitinib for RCC are presented.

Axitinib inhibits VEGFR-1, VEGFR-2 and VEGFR-3 with picomolar potencies, and PDGFR-alpha, PDGFR-beta and c-kit with nanomolar potencies. Phase II clinical trials of axitinib in pretreated RCC following sorafenib or cytokine treatment have demonstrated promising activity accompanied by a favorable toxicity profile. Further development of axitinib for RCC is warranted.

Written by
Sonpavde G, Hutson TE, Rini BI.

Reference
Expert Opin Investig Drugs. 2008 May;17(5):741-8.
doi:10.1517/13543784.17.5.741

PubMed Abstract
PMID:18447599

UroToday.com Renal Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!